Eidos starts Phase III of AG10 in TTR amyloid cardiomyopathy

Eidos Therapeutics Inc. (NASDAQ:EIDX) began the two-part Phase III ATTRibute-CM trial evaluating AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy.

The primary

Read the full 206 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE